Stage-associated differences in the serum N- and O-glycan profiles of patients with non-small cell lung cancer.

The serum glycan profiles were significantly different between NSCLC and healthy control, and most of the glycosylation changes had occurred at early stage. Further evaluation is needed to examine the diagnostic value of the glycan markers identified in this study.